Exact Mass: 409.3321

Exact Mass Matches: 409.3321

Found 104 metabolites which its exact mass value is equals to given mass value 409.3321, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Veratramine

3-PIPERIDINOL, 5-METHYL-2-((1S)-1-((3S,6AR,11AS,11BR)-2,3,4,6,6A,11,11A,11B-OCTAHYDRO-3-HYDROXY-10,11B-DIMETHYL-1H-BENZO(A)FLUOREN-9-YL)ETHYL)-, (2S,3R,5S)-

C27H39NO2 (409.2981)


Veratramine is a piperidine alkaloid comprising the 14,15,16,17-tetradehydro derivative of veratraman having two hydroxy groups at the 3- and 23-positions. It derives from a hydride of a veratraman. Veratramine is a natural product found in Veratrum grandiflorum, Veratrum mengtzeanum, and other organisms with data available. Veratramine is a hypotensive alkaloid isolated from the rhizomes of Veratrum. A piperidine alkaloid comprising the 14,15,16,17-tetradehydro derivative of veratraman having two hydroxy groups at the 3- and 23-positions. D002317 - Cardiovascular Agents > D000959 - Antihypertensive Agents > D014704 - Veratrum Alkaloids Data obtained from a veratramine standard purchased from Logan Natural Products, Logan, Utah USA. Veratramine(NSC17821; NSC23880) is useful as a signal transduction inhibitor for treating tumors. Veratramine(NSC17821; NSC23880) is useful as a signal transduction inhibitor for treating tumors.

   

5-(3,4-Dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine

3-{[5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C23H39NO5 (409.2828)


5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine is an acylcarnitine. More specifically, it is an 5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 5-(3,4-dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-(5-Hexylfuran-2-yl)hexanoylcarnitine

3-{[6-(5-hexylfuran-2-yl)hexanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C23H39NO5 (409.2828)


6-(5-hexylfuran-2-yl)hexanoylcarnitine is an acylcarnitine. More specifically, it is an 6-(5-hexylfuran-2-yl)hexanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-(5-hexylfuran-2-yl)hexanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 6-(5-hexylfuran-2-yl)hexanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-(3,4-Dimethyl-5-propylfuran-2-yl)heptanoylcarnitine

3-{[7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C23H39NO5 (409.2828)


7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-(3,4-dimethyl-5-propylfuran-2-yl)heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-(5-Pentylfuran-2-yl)heptanoylcarnitine

3-{[7-(5-pentylfuran-2-yl)heptanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C23H39NO5 (409.2828)


7-(5-pentylfuran-2-yl)heptanoylcarnitine is an acylcarnitine. More specifically, it is an 7-(5-pentylfuran-2-yl)heptanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-(5-pentylfuran-2-yl)heptanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 7-(5-pentylfuran-2-yl)heptanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

8-(5-Butylfuran-2-yl)octanoylcarnitine

3-{[8-(5-butylfuran-2-yl)octanoyl]oxy}-4-(trimethylazaniumyl)butanoate

C23H39NO5 (409.2828)


8-(5-Butylfuran-2-yl)octanoylcarnitine is an acylcarnitine. More specifically, it is an 8-(5-butylfuran-2-yl)octanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 8-(5-Butylfuran-2-yl)octanoylcarnitine is therefore classified as a long chain AC. As a long-chain acylcarnitine 8-(5-Butylfuran-2-yl)octanoylcarnitine is generally formed through esterification with long-chain fatty acids obtained from the diet. The main function of most long-chain acylcarnitines is to ensure long chain fatty acid transport into the mitochondria (PMID: 22804748). Altered levels of long-chain acylcarnitines can serve as useful markers for inherited disorders of long-chain fatty acid metabolism. Carnitine palmitoyltransferase I (CPT I, EC:2.3.1.21) is involved in the synthesis of long-chain acylcarnitines (more than C12) on the mitochondrial outer membrane. Elevated serum/plasma levels of long-chain acylcarnitines are not only markers for incomplete FA oxidation but also are indicators of altered carbohydrate and lipid metabolism. High serum concentrations of long-chain acylcarnitines in the postprandial or fed state are markers of insulin resistance and arise from insulins inability to inhibit CPT-1-dependent fatty acid metabolism in muscles and the heart (PMID: 19073774). Increased intracellular content of long-chain acylcarnitines is thought to serve as a feedback inhibition mechanism of insulin action (PMID: 23258903). In healthy subjects, increased concentrations of insulin effectively inhibits long-chain acylcarnitine production. Several studies have also found increased levels of circulating long-chain acylcarnitines in chronic heart failure patients (PMID: 26796394). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Linoleoyl Glutamic acid

2-[(1-Hydroxyoctadeca-9,12-dien-1-ylidene)amino]pentanedioate

C23H39NO5 (409.2828)


N-linoleoyl glutamic acid, also known as N-linoleoyl glutamate belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Linoleic acid amide of Glutamic acid. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Linoleoyl Glutamic acid is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Linoleoyl Glutamic acid is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

linoleyl-l-carnitine

linoleyl-l-carnitine

C25H47NO3 (409.3556)


   

Octadecadienylcarnitine

3-Hydroxy-3-[(trimethylazaniumyl)methyl]henicosa-4,6-dienoic acid

C25H47NO3 (409.3556)


   

(5Z,8Z,11Z,14Z)-N-(4-Hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide

(5Z,8Z,11Z,14Z)-N-(4-Hydroxy-2-methylphenyl)-5,8,11,14-eicosatetraenamide

C27H39NO2 (409.2981)


   

VERATRAMINE

2-(1-{5-hydroxy-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁶]heptadeca-7,11,13,15-tetraen-14-yl}ethyl)-5-methylpiperidin-3-ol

C27H39NO2 (409.2981)


   

Malyngamide V

Malyngamide V

C23H39NO5 (409.2828)


   
   
   

Malyngamide W

Malyngamide W

C23H39NO5 (409.2828)


   

laxiracemosin F

laxiracemosin F

C27H39NO2 (409.2981)


   

mirabilene-A isonitrile

mirabilene-A isonitrile

C24H43NO4 (409.3192)


   

chaetochalasin A

chaetochalasin A

C27H39NO2 (409.2981)


   

(25S)-22betaN-spirosol-1,4-dien-3-one

(25S)-22betaN-spirosol-1,4-dien-3-one

C27H39NO2 (409.2981)


   

22alpha,23alpha-epoxy-solanida-4-en-3-one

22alpha,23alpha-epoxy-solanida-4-en-3-one

C27H39NO2 (409.2981)


   

AM1172

N-5Z,8Z,11Z,14Z-eicosatetraenyl-4-hydroxy-benzamide

C27H39NO2 (409.2981)


   

VDM-11

N-(4-hydroxy-2-methylphenyl)-5Z,8Z,11Z,14Z-eicosatetraenamide

C27H39NO2 (409.2981)


   

PGF2&alpha

N,N-diethyl-9α,11α,15S-trihydroxy-prosta-5Z,13E-dien-1-amide

C24H43NO4 (409.3192)


   

Lumula

N-ethyl-9α,11α-dihydroxy-15-oxo-20a,20b-dihomoprost-5-en-1-amide

C24H43NO4 (409.3192)


   

NA 23:4;O4

N-(9Z,12Z-octadecadienoyl)-glutamic acid

C23H39NO5 (409.2828)


   

N,N-Dibutyl-N-methyl-1-butanaminium dibutyl phosphate

N,N-Dibutyl-N-methyl-1-butanaminium dibutyl phosphate

C21H48NO4P (409.3321)


   

benzyl(heptadecyl)dimethylammonium chloride

benzyl(heptadecyl)dimethylammonium chloride

C26H48ClN (409.3475)


   

4-dodecyl-4-ethylmorpholinium ethyl sulphate

4-dodecyl-4-ethylmorpholinium ethyl sulphate

C20H43NO5S (409.2862)


   

bis(2-ethylhexyl) hydrogen phosphate, compound with morpholine (1:1)

bis(2-ethylhexyl) hydrogen phosphate, compound with morpholine (1:1)

C20H44NO5P (409.2957)


   

Glutamic acid linoleamide

Glutamic acid linoleamide

C23H39NO5 (409.2828)


   

(5E,8E,11E,14E)-N-(4-hydroxy-2-methylphenyl)icosa-5,8,11,14-tetraenamide

(5E,8E,11E,14E)-N-(4-hydroxy-2-methylphenyl)icosa-5,8,11,14-tetraenamide

C27H39NO2 (409.2981)


   

6-(5-Hexylfuran-2-yl)hexanoylcarnitine

6-(5-Hexylfuran-2-yl)hexanoylcarnitine

C23H39NO5 (409.2828)


   

8-(5-Butylfuran-2-yl)octanoylcarnitine

8-(5-Butylfuran-2-yl)octanoylcarnitine

C23H39NO5 (409.2828)


   

7-(5-Pentylfuran-2-yl)heptanoylcarnitine

7-(5-Pentylfuran-2-yl)heptanoylcarnitine

C23H39NO5 (409.2828)


   

5-(3,4-Dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine

5-(3,4-Dimethyl-5-pentylfuran-2-yl)pentanoylcarnitine

C23H39NO5 (409.2828)


   

7-(3,4-Dimethyl-5-propylfuran-2-yl)heptanoylcarnitine

7-(3,4-Dimethyl-5-propylfuran-2-yl)heptanoylcarnitine

C23H39NO5 (409.2828)


   

(12E,15E)-3-hydroxy-3-[(trimethylazaniumyl)methyl]henicosa-12,15-dienoate

(12E,15E)-3-hydroxy-3-[(trimethylazaniumyl)methyl]henicosa-12,15-dienoate

C25H47NO3 (409.3556)


   

(4E,6E)-3-hydroxy-3-[(trimethylazaniumyl)methyl]henicosa-4,6-dienoate

(4E,6E)-3-hydroxy-3-[(trimethylazaniumyl)methyl]henicosa-4,6-dienoate

C25H47NO3 (409.3556)


   

N-Linoleoyl Glutamic acid

N-Linoleoyl Glutamic acid

C23H39NO5 (409.2828)


   

26-Oxohexacosanoate

26-Oxohexacosanoate

C26H49O3- (409.3682)


An omega-oxo fatty acid anion that is the conjugate base of 26-oxohexacosanoic acid, obtained by deprotonation of the carboxy group; major species at pH 7.3.

   

7-cyclohexyl-3-(4-morpholinyl)-1-(1-piperidinyl)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile

7-cyclohexyl-3-(4-morpholinyl)-1-(1-piperidinyl)-6,8-dihydro-5H-2,7-naphthyridine-4-carbonitrile

C24H35N5O (409.2841)


   

(2S)-5-amino-2-{[(9Z)-octadec-9-enoyl]amino}-5-oxopentanoate

(2S)-5-amino-2-{[(9Z)-octadec-9-enoyl]amino}-5-oxopentanoate

C23H41N2O4- (409.3066)


   

(2S)-2-{[(9Z)-octadec-9-enoyl]amino}pentanedioate

(2S)-2-{[(9Z)-octadec-9-enoyl]amino}pentanedioate

C23H39NO5-2 (409.2828)


   

C20 sphinganine 1-phosphate

C20 sphinganine 1-phosphate

C20H44NO5P (409.2957)


   

(9Z,12Z)-N-(1,3-dihydroxyoctan-2-yl)heptadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxyoctan-2-yl)heptadeca-9,12-dienamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]heptanamide

N-[(4E,8E)-1,3-dihydroxyoctadeca-4,8-dien-2-yl]heptanamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxytricosa-4,8-dien-2-yl]acetamide

N-[(4E,8E)-1,3-dihydroxytricosa-4,8-dien-2-yl]acetamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]octanamide

N-[(4E,8E)-1,3-dihydroxyheptadeca-4,8-dien-2-yl]octanamide

C25H47NO3 (409.3556)


   

(9Z,12Z)-N-(1,3-dihydroxynonan-2-yl)hexadeca-9,12-dienamide

(9Z,12Z)-N-(1,3-dihydroxynonan-2-yl)hexadeca-9,12-dienamide

C25H47NO3 (409.3556)


   

(Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]hexadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]hexadec-9-enamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxyhenicosa-4,8-dien-2-yl]butanamide

N-[(4E,8E)-1,3-dihydroxyhenicosa-4,8-dien-2-yl]butanamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxydocosa-4,8-dien-2-yl]propanamide

N-[(4E,8E)-1,3-dihydroxydocosa-4,8-dien-2-yl]propanamide

C25H47NO3 (409.3556)


   

(Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]heptadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxyoct-4-en-2-yl]heptadec-9-enamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]nonanamide

N-[(4E,8E)-1,3-dihydroxyhexadeca-4,8-dien-2-yl]nonanamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]pentanamide

N-[(4E,8E)-1,3-dihydroxyicosa-4,8-dien-2-yl]pentanamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]hexanamide

N-[(4E,8E)-1,3-dihydroxynonadeca-4,8-dien-2-yl]hexanamide

C25H47NO3 (409.3556)


   

(Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]tetradec-9-enamide

(Z)-N-[(E)-1,3-dihydroxyundec-4-en-2-yl]tetradec-9-enamide

C25H47NO3 (409.3556)


   

(Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]pentadec-9-enamide

(Z)-N-[(E)-1,3-dihydroxydec-4-en-2-yl]pentadec-9-enamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]undecanamide

N-[(4E,8E)-1,3-dihydroxytetradeca-4,8-dien-2-yl]undecanamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]decanamide

N-[(4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]decanamide

C25H47NO3 (409.3556)


   

(Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]tridec-9-enamide

(Z)-N-[(E)-1,3-dihydroxydodec-4-en-2-yl]tridec-9-enamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]dodecanamide

N-[(4E,8E)-1,3-dihydroxytrideca-4,8-dien-2-yl]dodecanamide

C25H47NO3 (409.3556)


   

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]tridecanamide

N-[(4E,8E)-1,3-dihydroxydodeca-4,8-dien-2-yl]tridecanamide

C25H47NO3 (409.3556)


   

N-[(2S,3R,4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]decanamide

N-[(2S,3R,4E,8E)-1,3-dihydroxypentadeca-4,8-dien-2-yl]decanamide

C25H47NO3 (409.3556)


   

N-[(2S,3R,4E,6E)-1,3-dihydroxypentadeca-4,6-dien-2-yl]decanamide

N-[(2S,3R,4E,6E)-1,3-dihydroxypentadeca-4,6-dien-2-yl]decanamide

C25H47NO3 (409.3556)


   

2-hydroxyhexacosenoate

2-hydroxyhexacosenoate

C26H49O3 (409.3682)


A 2-hydroxy fatty acid anion with a chain that is composed of 26 carbons and 1 double bond (position unspecified).

   

SPHP(20:0)

SPHP(d20:0)

C20H44NO5P (409.2957)


Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved

   

NA-2AAA 17:2(9Z,12Z)

NA-2AAA 17:2(9Z,12Z)

C23H39NO5 (409.2828)


   

NA-Ala 22:1(11Z)

NA-Ala 22:1(11Z)

C25H47NO3 (409.3556)


   

NA-Glu 18:2(9E,12E)

NA-Glu 18:2(9E,12E)

C23H39NO5 (409.2828)


   

NA-Glu 18:2(9Z,12Z)

NA-Glu 18:2(9Z,12Z)

C23H39NO5 (409.2828)


   

NA-Ile 19:1(9Z)

NA-Ile 19:1(9Z)

C25H47NO3 (409.3556)


   

NA-Leu 19:1(9Z)

NA-Leu 19:1(9Z)

C25H47NO3 (409.3556)


   

NA-Thr 20:2(11Z,14Z)

NA-Thr 20:2(11Z,14Z)

C24H43NO4 (409.3192)


   

NA-Val 20:1(11Z)

NA-Val 20:1(11Z)

C25H47NO3 (409.3556)


   
   
   

Cer 14:2;O2/11:0

Cer 14:2;O2/11:0

C25H47NO3 (409.3556)


   

Cer 15:2;O2/10:0

Cer 15:2;O2/10:0

C25H47NO3 (409.3556)


   

Cer 18:1;O2/7:1

Cer 18:1;O2/7:1

C25H47NO3 (409.3556)


   
   

Cer 8:0;O2/17:2

Cer 8:0;O2/17:2

C25H47NO3 (409.3556)


   

ST 21:0;O3;Gly

ST 21:0;O3;Gly

C23H39NO5 (409.2828)


   

Penbutolol (sulfate)

Penbutolol (sulfate)

C18H29NO2.1/2H2SO4 (409.3437)


Penbutolol sulfate is able to bind to both beta-1 adrenergic receptors and beta-2 adrenergic receptors (the two subtypes), thus making it a non-selective β blocker. Penbutolol is a sympathomimetic drug,used in the treatment of high blood pressure.

   

(2r,3s,5r)-2-[(1r)-1-[(3s,6as,11as,11br)-3-hydroxy-10,11b-dimethyl-1h,2h,3h,4h,6h,6ah,11h,11ah-cyclohexa[a]fluoren-9-yl]ethyl]-5-methylpiperidin-3-ol

(2r,3s,5r)-2-[(1r)-1-[(3s,6as,11as,11br)-3-hydroxy-10,11b-dimethyl-1h,2h,3h,4h,6h,6ah,11h,11ah-cyclohexa[a]fluoren-9-yl]ethyl]-5-methylpiperidin-3-ol

C27H39NO2 (409.2981)


   

2-[(1r)-1-[(1r,3as,3bs,7s,9ar,9bs,11ar)-7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-5-methylpyridin-3-ol

2-[(1r)-1-[(1r,3as,3bs,7s,9ar,9bs,11ar)-7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-5-methylpyridin-3-ol

C27H39NO2 (409.2981)


   

2-[(1r)-1-[(1r,3as,3bs,7s,9ar,9bs,11as)-7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-5-methylpyridin-3-ol

2-[(1r)-1-[(1r,3as,3bs,7s,9ar,9bs,11as)-7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]ethyl]-5-methylpyridin-3-ol

C27H39NO2 (409.2981)


   

methylidene(8,10,12,14-tetramethoxy-5,7-dimethylheptadeca-4,6,16-trien-2-yl)amine

methylidene(8,10,12,14-tetramethoxy-5,7-dimethylheptadeca-4,6,16-trien-2-yl)amine

C24H43NO4 (409.3192)


   

9-hydroxy-7-isopropyl-4,5,16,18,20-pentamethyl-8-azapentacyclo[10.8.0.0²,¹⁰.0⁶,¹⁰.0¹⁵,²⁰]icosa-3,8,13-trien-11-one

9-hydroxy-7-isopropyl-4,5,16,18,20-pentamethyl-8-azapentacyclo[10.8.0.0²,¹⁰.0⁶,¹⁰.0¹⁵,²⁰]icosa-3,8,13-trien-11-one

C27H39NO2 (409.2981)


   

methylidene[(2s,4e,6e,8s,10s,12s,14s)-8,10,12,14-tetramethoxy-5,7-dimethylheptadeca-4,6,16-trien-2-yl]amine

methylidene[(2s,4e,6e,8s,10s,12s,14s)-8,10,12,14-tetramethoxy-5,7-dimethylheptadeca-4,6,16-trien-2-yl]amine

C24H43NO4 (409.3192)


   

(4e,7s)-n-{2-[(4r,5r)-4-hydroxy-5-methyl-6-oxocyclohex-1-en-1-yl]-2-methoxyethyl}-7-methoxydodec-4-enimidic acid

(4e,7s)-n-{2-[(4r,5r)-4-hydroxy-5-methyl-6-oxocyclohex-1-en-1-yl]-2-methoxyethyl}-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

2-(1-{7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-5-methylpyridin-3-ol

2-(1-{7-hydroxy-9a,11a-dimethyl-1h,2h,3h,3ah,3bh,4h,6h,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl}ethyl)-5-methylpyridin-3-ol

C27H39NO2 (409.2981)


   

(2s,3r,5s)-2-[(1r)-1-[(3s,6ar,11as,11br)-3-hydroxy-10,11b-dimethyl-1h,2h,3h,4h,6h,6ah,11h,11ah-cyclohexa[a]fluoren-9-yl]ethyl]-5-methylpiperidin-3-ol

(2s,3r,5s)-2-[(1r)-1-[(3s,6ar,11as,11br)-3-hydroxy-10,11b-dimethyl-1h,2h,3h,4h,6h,6ah,11h,11ah-cyclohexa[a]fluoren-9-yl]ethyl]-5-methylpiperidin-3-ol

C27H39NO2 (409.2981)


   

3-[(1s,2r,4as,4bs,7s,8r,8as,10as)-7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl]-1h-indol-6-ol

3-[(1s,2r,4as,4bs,7s,8r,8as,10as)-7-hydroxy-1,2,4a,8,8a-pentamethyl-decahydro-2h-phenanthren-1-yl]-1h-indol-6-ol

C27H39NO2 (409.2981)


   

n-[2-(6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl)-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

n-[2-(6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl)-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

n-[2-(4-hydroxy-5-methyl-6-oxocyclohex-1-en-1-yl)-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

n-[2-(4-hydroxy-5-methyl-6-oxocyclohex-1-en-1-yl)-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

(4e,7r)-n-[(2r)-2-[(1r,6r)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

(4e,7r)-n-[(2r)-2-[(1r,6r)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

4-[(1r,3as,7r,9ar,9br,11as)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1h-pyrrole-2-carbaldehyde

4-[(1r,3as,7r,9ar,9br,11as)-7-hydroxy-3a,6,6,9a,11a-pentamethyl-1h,2h,3h,5h,5ah,7h,8h,9h,9bh,10h,11h-cyclopenta[a]phenanthren-1-yl]-1h-pyrrole-2-carbaldehyde

C27H39NO2 (409.2981)


   

(4e,7s)-n-[(2s)-2-[(1s,6s)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

(4e,7s)-n-[(2s)-2-[(1s,6s)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

(4e,7r)-n-[(2r)-2-[(1r,6s)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

(4e,7r)-n-[(2r)-2-[(1r,6s)-6-hydroxy-3-methyl-2-oxocyclohex-3-en-1-yl]-2-methoxyethyl]-7-methoxydodec-4-enimidic acid

C23H39NO5 (409.2828)


   

(1s,2s,5r,6r,7s,10r,12s,15s,16r,18s,20s)-9-hydroxy-7-isopropyl-4,5,16,18,20-pentamethyl-8-azapentacyclo[10.8.0.0²,¹⁰.0⁶,¹⁰.0¹⁵,²⁰]icosa-3,8,13-trien-11-one

(1s,2s,5r,6r,7s,10r,12s,15s,16r,18s,20s)-9-hydroxy-7-isopropyl-4,5,16,18,20-pentamethyl-8-azapentacyclo[10.8.0.0²,¹⁰.0⁶,¹⁰.0¹⁵,²⁰]icosa-3,8,13-trien-11-one

C27H39NO2 (409.2981)


   

(1r,2r,5s,6s,7r,10s,12r,15r,16s,18r,20r)-9-hydroxy-7-isopropyl-4,5,16,18,20-pentamethyl-8-azapentacyclo[10.8.0.0²,¹⁰.0⁶,¹⁰.0¹⁵,²⁰]icosa-3,8,13-trien-11-one

(1r,2r,5s,6s,7r,10s,12r,15r,16s,18r,20r)-9-hydroxy-7-isopropyl-4,5,16,18,20-pentamethyl-8-azapentacyclo[10.8.0.0²,¹⁰.0⁶,¹⁰.0¹⁵,²⁰]icosa-3,8,13-trien-11-one

C27H39NO2 (409.2981)